Purpose: Proteasome inhibitors (PI) are the backbone of various treatment regimens in
multiple myeloma. We recently described the first in-patient point mutations affecting the 20S …

Background: Various treatment regimen in multiple myeloma (MM) are based on
proteasome inhibition (PI). Although effective at therapy start, most patients relapse and …

Multiple myeloma (MM) is a cancer caused by uncontrolled proliferation of antibody-
secreting plasma cells in bone marrow, which represents the second most common …

Multiple myeloma (MM) is an incurable disease characterized by clonal expansion of
malignant plasma cells in the bone marrow [1]. Although the advent of novel therapeutics …

Despite an increasing number of approved therapies, multiple myeloma (MM) remains an
incurable disease and only a small number of patients achieve prolonged disease control …

Introduction: Proteasome inhibition is the backbone of various Multiple Myeloma (MM)
treatment regimens, leading to durable responses and high quality remissions. However …

Variations within proteasome β (PSMB) genes, which encode the β subunits of the 20S
proteasome, may affect proteasome function, assembly, and/or binding of proteasome …

Gene expression profiling (GEP) of purified plasma cells 48 hours after thalidomide and
dexamethasone test doses showed these agents' mechanisms of action and provided …

We generated eight multiple myeloma cell lines resistant to bortezomib; five acquired
PSMB5 mutations. In 1,500 patients such mutations were rare clinically. To better …

Bortezomib is a proteasome inhibitor important to the therapy of multiple myeloma (MM),
though a number of patients show resistance to this drug. To study the cellular basis of this …